BRAND_ANALYSIS #ASTRAZENECA HEALTH & PHARMA #15 OF 26 IN HEALTH & PHARMA INTERESTING

AstraZeneca

· Public · Updated 09 Apr 2026 08:47 UTC
#281 of 1208 overall by tension · #15 of 26 in Health & Pharma
16 Interesting
The Silent Giant
Analysis

AstraZeneca occupies the peculiar position of a pharma giant with genuine cultural traction (C=57), yet the 16-point gap to business performance (B=73) suggests the public respects the science more than the brand. A 4.78% stock bump indicates markets trust execution over narrative.

IN THE NEWS (100 articles this week)
Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression - Fierce Pharma
AstraZeneca reports positive EMERALD-3 results for HCC - Clinical Trials Arena
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial - Reuters
Cultural Score
57 / 100
Business Score
73 / 100
TENSION▂▁▁▁▁▂▁▁▁▁▁▂▂▂
CULTURAL▄▄▄▄▄▄▄▄▅▅▅▄▄▄
BUSINESS▅▅▅▅▅▅▅▅▅▅▆▆▆▆
Loading...
Wikipedia Momentum 15/40
News Presence 43/35
Search InterestRedistributed to other dimensions
Stock Momentum 20/30
Market Position 22/25
Revenue Growth 15/25
Earnings Health 16/20
Avg Daily (7d)498
Avg Daily (90d)649
7d/90d Ratio0.77x
Price$204.27
30d Change+4.8%
Market Cap$316.7B
Profit Margin17.4%
AstraZeneca's tension is 16. Commerce outpacing culture. sociologyofcapitalism.com/brand/astrazeneca
SHARE ON X
EMBED
<iframe src="https://sociologyofcapitalism.com/embed/astrazeneca.html" width="320" height="200" frameborder="0"></iframe>